Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 3, 2002 - Issue 8
Submit an article Journal homepage
33
Views
1
CrossRef citations to date
0
Altmetric
Miscellaneous

Pharmacotherapeutic options for the management of myocardial infarction

Judy WM Cheng Address for correspondence, Associate Professor in Pharmacy Practice, Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, NY, USA, Clinical Pharmacy Specialist in Cardiology, Mount Sinai Medical Center, One Gustave L. Levy Place, Box 1211, New York, NY 10029, USA, Tel: +1 212 241 7718; Fax: +1 212 987 0198;, E-mail: [email protected]
Pages 1153-1168 | Published online: 25 Feb 2005

Bibliography

  • THEROUX P, FUSTER V: Acute coronary syndromes: unstable angina and non-Q-wave myocardial infarction. Circulation (1998) 97:1195–1206.
  • GRUNDY SM, BALADY GJ, CRIQUI MH et al.: Primary prevention of coronary heart disease: guidance from Framingham. Circulation (1998) 97:1876–1887.
  • THE JOINT EUROPEAN SOCIETY OF CARDIOLOGY/AMERICAN COLLEGE OF CARDIOLOGY COMMITTEE: Myocardial infarction redefined - a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. I Am. Coll Cardiol (2000) 36:959–969.
  • WU AHB, VALDES R, APPLE F et al.: Cardiac troponin-T immunoassay for diagnosis of acute myocardial infarction. Clin. Chem. (1994) 40(6):900–907.
  • HAMM CW, GOLDMAN GU, HEESCHEN C, KREYMANN G, BERGER J, MEINERTZ T: Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin T or troponin I. N Engl. I Med. (1997) 337:1648–1653.
  • LUSCHER MS, THYGESEN K, RAVKILDE J, HEICKENDORFF L for the TRIM STUDY GROUP: Applicability of cardiac troponin T and I for early risk stratification in unstable coronary artery disease. Circulation (1997) 96:2578–2585.
  • BURKE AP, FARB A, MALCOLM GT, LIANG YH, SMIALEK J, VIRMANI R: Coronary risk factors and plaque morphology in men with coronary artery disease who died suddenly. N Engl. I Med. (1997) 336:1276–1281.
  • DOERING LV: Pathophysiology of acute coronary syndromes leading to acute myocardial infarction. J. Cardiovasc. Nuts. (1999) 13(3):1–20.
  • DOBESH PP, LATHAM KA: Advancing the battle against acute ischemic syndromes: a focus on the GP IIb/IIIa inhibitors. Pharmacotherapy (1998) 18(4):663–685.
  • FUSTER V, JANG IK: Role of platelet inhibitor agents in coronary artery disease. In: Textbook of haterventional cardiology. 2nd ed. Vol. 1 . Topol EJ (Ed.), WB Saunders, PA, USA (1994):3–22.
  • HAINES ST, BUSSEY HI: Thrombosis and the pharmacology of antithrombotic agents. Ann. Pharmacother: (1995) 29:892–905.
  • FUSTER V, BADIMORE L, BADIMORE JJ, CHEESBORO JH: The pathogenesis of coronary artery disease and the acute coronary syndrome. N Engl. J. Med. (1992) 326:242–250.
  • FURIE B, FURIE BC: Molecular and cellular biology of blood coagulation. N Engl. J. Med. (1992) 326:800–6.
  • BATES SM, WEITZ JI: Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin. Am. I Cardiol (1998) 82:12P–18P
  • ACC and AHA Guidelines for the Management of Patients With Acute Myocardial Infarction 1999 Updated Guideline.
  • ••Most updated guidelines on treatment ofacute MI from the ACC and AHA.
  • ACC and AHA Guidelines for the Management of Patients with Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction 2002 Updated Guidelines.
  • ••Most updated guidelines on treatment ofnon-STE MI.
  • ISIS-2 COLLABORATIVE GROUP: Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected acute myocardial infarction: ISIS-2. Lancet (1988) 2:349-360. Classic study defining the role of aspirin in acute MI
  • BAIGER C, COLLINS R, APPLEBY P etal.: ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomized comparison of intravenous streptokinase, oral aspirin, both or either. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Br. Med. J. (1998) 316(7141):1337–1343.
  • CAPRIE STEERING COMMITTEE: A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet (1996) 348:1329–1339.
  • THE CURE INVESTIGATORS: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl. J. Med. (2001) 345(7):494–502.
  • ••Study defining the role of usingclopidogrel in addition to aspirin in patients with ACS.
  • GASPOZ JM, COXSON PG, GOLDMAN PA et al.: Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary artery disease. N Engl. J. Med. (2002) 346:1800–1806.
  • BENNETT CL, CONNORS JM, CARWILE JM et al: thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl. J. Med. (2000) 342:1773–1777.
  • MAURO LS, BOROVICKA MC, KLINE SS: Introduction to coronary artery stents and their pharmacotherapeutic manage-ment. Ann. Pharmacother. (1997) 31:1490–1498.
  • BERGER PB, BELL! MR, RIHAL CS,34.TING H, BARSNESS G, GARRATT K: Clopidogrel versus ticlopidine after intracoronary stent placement. J. Am. Coll Cardiol. (1999) 34:1891–1894.
  • MOUSSA I, OETGEN M, ROUBIN G,••COLOMBO A, WANG X, WE S: Effectiveness of clopidogrel and aspirin35. versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. Circulation (1999) 99:2364–2366.
  • MISHKEL GJ, AGUIRRE FV, LIGON RW, ROCHA-SINGH KJ, LUCORE CL: Clopidogrel as adjunctive antiplatelet therapy during coronary stenting." Am. Coll. Cardiol. (1999) 34:1884–1890.
  • MULLER C, BUTTNER HJ, PETERSEN J, ROSKAMM H: A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents. Circulation (2000) 101:590–593.
  • BERTRAND ME, RUPPRESCHT HJ, URBAN P, GERSHLICK AH: Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting. Circulation (2000) 102:624–629.
  • BRAUNWALD E: Unstable angina. An etiologic approach to management. Circulation (1998) 98:2219–2222.
  • THE EPISTENT INVESTIGATORS: Randomized placebo-controlled and balloon-angioplasty controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet (1998) 352:87–92.
  • THE CAPTURE INVESTIGATORS: Randomized placebo controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet. (1997) 349(9063):1429.
  • THE PRISM INVESTIGATORS: A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl. J. Med. (1998) 338:1498–1505.
  • THE PRISM-PLUS INVESTIGATORS: Inhibition of the platelet glycoprotein IIb/ Ma receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl. I Med. (1998) 338:1488–1497.
  • ••Study defining the role of tirofiban used inpatients with non-STE MI. THE PURSUIT TRIAL INVESTIGATORS: Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndrome. N Engl. J. Med. (1998) 339:436-443. Study defining the role of epitifibatide used in patients with non-STE MI.
  • IMPACT II INVESTIGATORS: Randomized placebo controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT II. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis II. Lancet (1997) 349:1422–1428.
  • RESTORE INVESTIGATORS: Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina and acute myocardial infarction undergoing coronary angioplasty. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. Circulation (1997) 96:1445–1452.
  • THE EPIC INVESTIGATORS: Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl. I Med. (1994) 330:956–961.
  • THE EPILOG INVESTIGATORS: Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl. J. Med. (1997) 336:1689–1696.
  • GUSTO IV-ACS INVESTIGATORS: Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomized trial. Lancet (2001) 357(9272):1915–1924.
  • THE ESPRIT INVESTIGATORS: Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomized, placebo-controlled trial. Lancet (2000) 356(9247):2037–2044.
  • TOPOL EJ, MOLITERNO DJ, HERRMANN HC et al.: Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl. J. Med. (2001) 344(25):1888–1894.
  • GISSI INVESTIGATORS: Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet (1986) 1:397–401.
  • ISIS-2 COLLABORATIVE GROUP: Randomized trial of intravenous streptokinase, oral aspirin, or neither among 17187 cases of suspected myocardial infarction. Lancet (1988) 2(8):349–360.
  • GUSTO INVESTIGATORS: An international randomized trial comparing four thrombolytic stratifies for acute myocardial infarction. N Engl. I Med. (1993) 329:673–682.
  • ••Classic study defining that if alteplase isgiven in a front-load regimen, its efficacy is better then streptokinase.
  • LATE INVESTIGATORS: Late Assessment of Thrombolytic Efficacy (LATE) study with alteplase 6 to 24 hours after onset of acute myocardial infarction. Lancet (1993) 342:759–766.
  • GOLDBERG RJ, YARZEBSKI JL, LESSARD DM, GORE JM: Decade long trends (1986-1997), and factors associated with time to hospital presentation in patients with acute myocardial infarction (The Worcerter Heart Attack Study). Arch. Intern. Med. (2000) 160:3217–3223.
  • THE GUSTO INVESTIGATORS: A comparison of reteplase with alteplase for acute myocardial infarction. N Engl. J. Med. (1997) 337:1118–1123.
  • SEYEDROUDBARI A, KESSLER ER, MOOSS AN, WURDEMAN RL, BALA M, HILLEMAN DE: Time to treatment and cost of thrombolysis: a multicenter comparison of tPA and rPA. I Thromb. (2000) 9:303–341.
  • THE ASSENT-2 INVESTIGATORS: Single bolus tenecteplase compared with frontloaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomized trial. Assessment of the Safety and Efficacy of a New Thrombolytic Investigators. Lancet. (1999) 354(9180):716–722.
  • THE GUSTO ANGIOGRAPHIC INVESTIGATORS: The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction. N Engl. I Med. (1993) 329:1615–622.
  • KENNEDY JVV, STADIUS ML: Combined thrombolytic and platelet glycoprotein IIb/IIIa inhibitor therapy for acute myocardial infarction. Circulation (1999) 329:1615–1622.
  • CALIFF RM: Glycoprotein IIb/IIIa blockade and thrombolytics: early lessons from the SPEED and GUSTO IV trials. Am. Heart 1. (1999) 138(Suppl.):S12–S15.
  • CANNON CP: Overcoming thrombolytic resistance. J. Am. Coll. Cardiol (1999) 34:1395–1402.
  • COLLER BS: Platelets and thrombolytictherapy. N Engl. J. Med. (1990) 322:33–42.
  • VAUGHAN DE, VAN HOUTTE E, DECLERCK PJ, COLLEN D: Streptokinase-induced platelet aggregation: prevalence and mechanism. Circulation (1991) 84:84–91.
  • THE GUSTO V INVESTIGATORS: Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomized trial. Lancet (2001) 357:1905–1914.
  • THE ASSENT-3 INVESTIGATORS: Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomized trial in acute myocardial infarction. Lancet (2001) 358:605–613.
  • THE RISC GROUP: Risk of myocardialinfarction and death during treatment with low-dose aspirin and intravenous heparin in men with unstable angina. Lancet (1990) 336:827–830.
  • COHEN M, ADAMS PC, PARRY G et al: Combinations antithrombotic therapy in unstable rest angina and non-Q-wave infarction in non-prior aspirin users. Circulation (1994) 89:81–88.
  • FRISC INVESTIGATORS: Invasive compared with non-invasive treatment in unstable coronary artery disease: FRISC II prospective randomized multicentre study. Lancet (1999) 354(9180):708–715.
  • ERIC INVESTIGATORS: Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Circulation (1997) 96:61–68.
  • ESSENCE STUDY GROUP: A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl. J. Med. (1997) 337:447–452.
  • ••Study defining the role of enoxaparin usein patients with ACS, suggesting that enoxaparin may be better then intravenous heparin.
  • FRISC INVESTIGATORS: Low-molecular weight heparin during instability in coronary artery disease. Lancet (1996) 347:561–568.
  • ANTMAN EM, MCCABE CH, GURFINKEL EP et al.: Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the Thrombolysis In Myocardial Infarction (TIMI) 11B Trial. Circulation (1999) 100: 1593-1601.
  • EIKELBOOM JW, SNAND SS, MALMBERG K et al.: Unfractionated heparin and low-molecular weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet (2000) 355:1936–1942.
  • SERRUYS RW, HERRMAN JPR, SIMON R et al.: A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. N Engl. I Med. (1995) 333:757–763.
  • BITTL JA, SRONY J, BRINKER JA et al: Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or post-infarction angina. N Engl. J. Med. (1995) 333:764–769.
  • GUSTO IIb INVESTIGATORS: A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndrome. N Engl. J. Med. (1996) 335:775–782.
  • TIMI 9B INVESTIGATORS: Hirudin inacute myocardial infarction. Circulation (1996) 94:911–921.
  • HERO TRIAL INVESTIGATORS: Randomized, double-blinded comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction. Circulation (1997) 96:2155–2161.
  • OASIS INVESTIGATORS: Comparison ofthe effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation. Circulation (1997) 96:769–777.
  • OASIS-2 INVESTIGATORS: Effects of recombinant hirudin (lepirudin) compared to heparin on death, myocardial infarction, refractory angina, and revascularization procedures in patients with acute myocardial ischemia without ST elevation: a randomized trial. Lancet (1999) 353:429–438.
  • ACC and AHA/ACP-ASIM Guidelines for the management of patients with chronic stable angina. A report of the American College of Cardiology/American Heart Association Task Force for practice guidelines (Committee on Management of Patients with Chronic Stable Angina). Am. Coll. Cardiol (1999) 33(7):2093–2190.
  • ••Latest guideline from AHA and ACC inthe management of patients with chronic stable angina.
  • THE NORWEGIAN MULTICENTER STUDY GROUP: Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl. I Med. (1981) 304:801–807.
  • BETA-BLOCKER HEART ATTACK TRIAL RESEARCH GROUP: A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. "AMA (1982) 247:1701–1714.
  • ROBERT R, ROGERS WJ, MUELLER HS et al: Immediate versus deferred 13-blockade following thrombolytic therapy in patients surviving acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study. Circulation (1991) 83:422–437.
  • THE MIAMI TRIAL RESEARCH GROUP: Metoprolol in acute myocardial infarction (MIAMI): a randomized placebo-controlled international trial. Eur. Heart (1985) 6:199–226.
  • ISIS-1 COLLABORATIVE GROUP: Randomized trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction: ISIS-1. Lancet (1986) 2:57–66.
  • ISIS-4 COLLABORATIVE GROUP: ISIS-4: a randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet (1995) 345:669–685.
  • ••Classic study defining that the use of earlyACEI post-MI significantly improve mortality and morbidity. The use of oral mononitrate and intravenous magnesium sulfate have no impact on morbidity and mortality.
  • GISSI-3: Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet (1994) 343:1115–1122.
  • ••Classic study defining that the use of earlyACEI post-MI significantly improve mortality and morbidity. The use of oral mononitrate and intravenous magnesium sulfate have no impact on morbidity and mortality.
  • PFEFFER MA, BRAUNWALD E, MOYE LA et al.: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl. I Med. (1992) 327:669–677.
  • THE AIRE STUDY INVESTIGATORS: Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet (1993) 342:821–828.
  • AMBROSIONI E, BORGHO C, MAGNANI B: The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction: the Survival of Myocardial Infarction: Long-Term Evaluation (SMILE) Study Investigators. N Engl. J. Med. (1995) 332:80–85.
  • KOBER L, TORP-PEDERSEN C, CARSLEN JE et al.: A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl. J. Med. (1995) 333:1670–1676.
  • SWEDBERG K, HELD P, KJEKSHUS J, RASMUSSEN K, RYDEN L, WEDEL1 H: Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction: results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl. J. Med. (1992) 327:678–684.
  • YUSUF S, SLEIGHT P, POGUE J, BOSCH J, DAVIES R, DAGENAIS G: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl. J. Med. (2000) 342:145–152.
  • JUGDUTT BI, WARNICA JW: Intravenous nitroglycerin therapy to limit myocardial infarct size, expansion, and complications: effect of timing, dosage, and infarction location. Circulation (1988) 78:906–919.
  • YUSUF S, COLLINS R, MACMAHON S, PETO R: Effect of intravenous nitrates on mortality following acute myocardial infarction: a multicenter study. Eur. Heart I. (1988) 1:1088–1092.
  • ECHT DS, LIEBSON PR, MITCHELL1 LB et al.: Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the Cardiac Arrhythmia Suppression Trial. N Engl. I Med. (1991) 324:781–788.
  • ••The first classic study defining thatantiaiThythmic agents should not be used routinely post-MI to prevent cardiac arrhythmia. The proarrhythmic effect may outweigh their benefits.
  • THE CARDIAC ARRHYTHMIA SUPPRESSION TRIAL II INVESTIGATORS: Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl. I Med. (1992) 327:227–233.
  • WALDO AL, CAMM AJ, DERUYTER H et al.: Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet (1996) 348:7–12.
  • CAIRNS JA, CONNONLLY SJ, ROBERTS R et al.: Randomized trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarization: CAMIAT. Lancet (1997) 349:675–682.
  • ••Canadian study defining that the use ofarniodarone post MI has no effect on all cause mortality but reduce the risk of death induced by arrhythmia.
  • JULIAN DG, CAMM AJ, FRANGIN G et al.: Randomized trial of effect of amiodarone on mortality in patients with left ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet (1997) 349:667–674.
  • ••Similar to the CAMIAC study, this is aEuropean study defining that the use of arniodarone post MI has no effect on all cause mortality but reduce the risk of death induced by arrhythmia.
  • ASPECT RESEARCH GROUP: Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction: anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. Lancet (1994) 343:499–503.
  • SACKS FM, PFEIFFER MA, MOYE LA et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl. J. Med. (1996) 335:1001–1009.
  • THE LIPID STUDY GROUP: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl. I Med. (1998) 339:1349–1357.
  • SHEPHERD J, COBBE SM, FORD I et al.: Prevention of coronary heart disease with pravastatin in patients with hypercholesterolemia. N Engl. j Med. (1995) 333:1301–1307.
  • DOWNS JR, CLEARFIELD M, WEIS Set al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol events. "AMA (1998) 279:1615–1622.
  • SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY GROUP: Randomized trial of cholesterol lowering in 4444 patients with coronary artery disease: the Scandinavian Simvastatin Survival Study (4S). Lancet (1994) 344:1383–1389.
  • ••First study demonstrating the beneficialeffects of HMGC0-A reductase inhibitors in patients post-MI for secondary prevention of cardiovascular events.
  • BROWN G, ALBERS JJ, FRISHER LD et al.: Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl. J. Med. (1990) 323:1289–1298.
  • BLANKENHORN DH, AZEN SP, KRAMSCH DM et al.: Coronary angiographic changes with lovastatin: the Monitored Atherosclerosis Regression Study (MARS). Ann. Intern. Med. (1993) 119:969–976.
  • WATERS D, HIGGINSON L, GLADSTONE P et al.: Effects of monotherapy with HMG Co-A reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: the Canadian Coronary Atherosclerosis Intervention Trial. Circulation (1994) 89:959–968.
  • MAAS INVESTIGATORS: Effect of simvastatin on coronary atheroma: the Multicenter Anti-Atheroma Study (MAAS). Lancet (1994) 344:633–638.
  • JUKEMA JW, BRUSCHKE AVG, VAN BOVEN AK et al.: Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation (1995) 91:2528–2540.
  • PITT B, MANCINI GBJ, ELLIS SG et al: Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I).' Am. Coll. Cardiol (1994) 344:633–638.
  • FOLLAND ED, VOGEL RA, HARTIGAN P et al.: Relation between coronary artery stenosis assessed by visual, caliper, and computer methods and exercise capacity in patients with single vessel coronary artery disease. Circulation. (1994) 89:959–968.
  • AMBROSE JA, TANNENBAUM MA, ALEXOPOULOS D et al.: Angiographic progression of coronary artery disease and the development of myocardial infarction.' Am. Coll. Cardiol (1988) 12:52–62.
  • KNOPP — .VP'1-1-: Drug treatment of lipid disorders. N Engl. J. Med. (1999) 341:498–511.
  • CANNER PL, BERGE KG, WENGER NK et al.: Fifteen-year mortality in coronary drug project patients: long-term benefit with niacin. J. Am. Coll. Cardiol (1986) 8:1245–1255.
  • RUBINS HB, ROBINS SJ, COLLINS D et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl. J. Med. (1999) 341:410–418.
  • FRICK MH, HEINONEN OP, HUTTUNEN JK, KOSKINEN P, MANNTTARI M, MANNINEN V: Efficacy of gemfibrozil in dyslipidemic subjects with suspected heart disease. An ancillary study in the Helsinki Heart Study frame population. Ann. Med. (1993) 25:41–45.
  • THE BIP STUDY GROUP: Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) study. Circulation (2000) 102:21–27.
  • GOTTO AM Jr: Triglyceride as a risk factor for coronary artery disease. Am. J. Cardiol (1998) 82(Suppl.):22Q–25Q.

Websites

  • http://www.americanheart.org/statistics/ index.html 2001 Heart and Stroke Statistics.
  • •This website also links to the downloads in references [15] and [16].

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.